This is not a small step. It is a calculated move backed by early clinical data, institutional expertise, and a clear gap in current treatment options.

A New Chapter for CAR-T Therapy in Children

CAR-T therapy refers to a form of immunotherapy where a patient’s own T-cells are modified to identify and attack cancer cells. In this case, Atla-cel targets CD19, a protein commonly found on B-cell leukemia cells.

Earlier CAR-T therapies proved effective. They helped patients reach remission. Yet safety concerns slowed broader use, especially in children. The biggest concern is ICANS (immune effector cell-associated neurotoxicity syndrome), a condition that can affect the brain.

For adults, ICANS is serious. For children, it raises even greater concern. The developing brain does not get a second chance.

That concern has kept many young patients from accessing CAR-T therapy at all.

Why Atla-cel Is Drawing Attention

Atla-cel introduces a third-generation design. That means changes at the cellular engineering level intended to improve both effectiveness and tolerability.

Early results from the Phase 1 ENABLE-1 trial, presented at the American Society of Hematology Annual Meeting in 2024, showed strong complete response rates in adults with lymphoma. More important, the therapy showed low rates of severe cytokine release syndrome (CRS) and sharply reduced ICANS.

Reduced neurotoxicity is not a minor improvement. It is the difference between a therapy being limited to hospital settings and one that could move into outpatient care.

That shift matters. It changes how long children stay in the hospital. It changes how families plan their lives. It changes access.

Clinical Program Expands Across Continents

The new paediatric clinical program will span the United States, New Zealand, and potentially Australia. Cincinnati Children’s will lead the global effort.

Dr. Stella M. Davies will serve as Principal Investigator. She brings extensive experience in paediatric hematology-oncology and bone marrow transplantation. Her leadership adds weight to the program’s clinical direction.

Cincinnati Children’s is not an incidental partner. The institution ranks among the top pediatric health systems in the United States and holds the number one position in cancer care according to U.S. News & World Report.

This partnership combines BioOra’s therapy development and manufacturing capabilities with Cincinnati Children’s clinical infrastructure and research leadership.

Leadership Signals Strong Commitment

BioOra CEO John Robson framed the partnership as a focused effort to improve outcomes for children with limited options. He emphasized that safer therapies must be part of the equation, not an afterthought.

Dr. Laurence Cooper, a paediatric oncologist and BioOra board member, highlighted the importance of reduced neurotoxicity. He made it clear that safety is central to whether CAR-T therapy can be used in children at all.

Dr. Stella Davies pointed to the persistent challenge of relapsed B-ALL. She noted that early safety signals make Atla-cel a strong candidate for paediatric evaluation.

Steve Davis, CEO of Cincinnati Children’s, reinforced the institution’s focus on delivering advanced therapies with a strong safety profile. His addition to BioOra’s Board of Directors signals deeper alignment between the two organizations.

Manufacturing and Scale: A Quiet Advantage

BioOra operates a dedicated GMP (Good Manufacturing Practice) facility in Christchurch, New Zealand. The site uses the Cocoon® platform, an automated system for cell therapy manufacturing.

Automation matters. It supports consistency. It reduces variability. It improves scalability.

In CAR-T therapy, manufacturing is often the bottleneck. BioOra’s approach attempts to remove that constraint.

What This Means for Patients and Families

Children with relapsed or refractory B-ALL often face limited options. Standard therapies lose effectiveness. Outcomes decline.

CAR-T therapy offered hope. Safety concerns limited access.

Atla-cel may change that balance. Lower neurotoxicity could allow broader use. It could reduce hospital stays. It could bring treatment closer to home.

Those are not abstract benefits. They affect real families dealing with long hospital visits, high costs, and uncertain outcomes.

Where This Effort Stands Now

The program is entering clinical development for paediatric patients. Adult data provides the foundation. The next phase will determine whether those results translate to children.

That translation is not automatic. Paediatric oncology has its own challenges. Yet the early signals are strong enough to justify moving forward.

This partnership brings together the right elements: clinical leadership, manufacturing capability, and a therapy with a differentiated safety profile.

If the data holds, Atla-cel could become a meaningful addition to the treatment landscape for childhood leukemia. It could also push the broader CAR-T field to rethink safety as a primary goal rather than a secondary consideration.

Sometimes progress comes in big leaps. Sometimes it comes from fixing what has held therapies back for years. This effort leans into the second path—and that may be exactly what the field needs.

The post A Safer CAR-T Breakthrough? BioOra and Cincinnati Children’s Target Childhood Leukemia appeared first on Health Plan News.

One in Three Americans Losing Sleep Over Healthcare Bills—And the Numbers Keep Getting Worse

A new national survey from Imagine360 paints a clear picture: healthcare costs are no longer just a budget issue. They are now a daily stressor affecting sleep, job decisions, and even medical outcomes. The data is blunt. One in three insured Americans says healthcare expenses have kept them awake at night. Nearly half are skipping care. That is not a minor trend. That is a warning sign.

Survey Scope and Methodology

Imagine360, an alternative health plan provider for self-funded employers, conducted its second annual healthcare affordability survey through Pollfish. The study included 2,500 insured adults across the United States.

The sample reflects a broad cross-section of the country. Respondents came from the South, Northeast, Midwest, and West. About 80 percent receive health coverage through an employer. Roughly one-third report household income at or below the national median of $83,730.

This is not a niche group. This is the American workforce.

Healthcare Costs Are Driving Real Behavior Changes

Skipping Care Is Becoming Common

Forty-four percent of respondents said they skipped or delayed medical care or prescriptions due to cost. That figure increased from 38 percent the prior year. The trend is moving in the wrong direction.

Even more concerning, 45 percent of those who delayed care reported their condition worsened. That creates a direct link between cost and declining health.

In plain terms, people are rolling the dice with their health because they cannot afford the bill.

The Sleep Factor Signals a Deeper Problem

Thirty-six percent of respondents reported losing sleep over healthcare costs. That is more than a financial concern. It is a health issue in its own right.

Sleep disruption affects focus, productivity, and long-term health. The Integrated Benefits Institute estimates this type of stress costs employers nearly $3,000 per employee each year.

It is a quiet drain on businesses. Employees show up tired. Work suffers. Absences increase. The ripple effect is real.

Healthcare Costs Are Reshaping Job Decisions

Benefits Now Compete Directly With Salary

Seventy-four percent of respondents said health benefits play a major role in choosing or staying with an employer. That is a sharp increase from the prior year.

Even more telling, 40 percent said they would accept a 10 percent pay cut in exchange for better health coverage.

That number rises to 45 percent among younger workers, including millennials and Gen Z. These groups now represent a large portion of the workforce.

This signals a shift. Salary still matters. But healthcare coverage now sits right next to it in importance.

Employers Are Feeling the Pressure

Employer-sponsored family health coverage is approaching $27,000 annually. Costs are expected to rise again in 2026, with increases nearing double digits.

For employers, this creates a balancing act. Higher costs strain budgets. Reduced benefits impact retention. Neither option is attractive.

Jeff Bak, CEO of Imagine360, summed it up clearly. He described the situation as a crisis point and warned that current cost structures are not sustainable.

Traditional Health Plans Are Facing Scrutiny

Value Perception Is Declining

Nearly two-thirds of respondents said the quality of care does not match the cost. That gap between price and perceived value is driving frustration.

People are asking a simple question: “Why am I paying this much?”

And right now, many are not satisfied with the answer.

Alternative Models Gain Attention

Employers are starting to look at different approaches. According to the Business Group on Health, many expect to explore alternative health plans by 2028.

Some of these models use reference-based pricing. This approach sets reimbursement rates based on a benchmark, often tied to Medicare rates, instead of traditional negotiated pricing.

Other models rely on direct provider contracting. Employers work directly with healthcare providers to control costs and improve transparency.

Independent actuarial analyses suggest these approaches can reduce overall healthcare spending by close to 20 percent without limiting access to care.

That kind of reduction gets attention fast.

The Bigger Picture for Employers and Employees

Healthcare affordability now affects more than medical decisions. It affects hiring. It affects retention. It affects productivity.

Employers must evaluate plan design, cost-sharing structures, and provider networks. Employees are watching closely. They are making decisions based on these factors.

At the same time, employees are weighing trade-offs. Pay versus benefits. Immediate income versus long-term health security.

That is not a choice most people want to make.

What This Means Going Forward

The survey results show a system under strain. Costs continue to rise. Access is becoming inconsistent. Outcomes are starting to reflect those pressures.

The warning signs are clear. People are skipping care. Health conditions are worsening. Stress levels are rising.

Healthcare has moved from a background expense to a front-and-center issue in everyday life. It now influences sleep, job choices, and financial stability.

If costs continue on this path, expect more employers to rethink their approach. Expect more employees to demand change. And expect healthcare benefits to remain one of the most closely watched parts of any compensation package.

The message is simple. The current system is straining under its own weight. Change is no longer optional. It is overdue.

This survey does not whisper. It speaks plainly. Americans are feeling the pressure, and they are starting to respond in ways that affect both their health and their livelihoods.

That should get everyone’s attention.

The post Survey: Healthcare Costs Are Keeping Americans Awake at Night appeared first on Health Plan News.

The deal, announced February 13, 2026, still requires regulatory approval and other standard closing steps. If completed as expected in the fourth quarter of 2026, AF Group will become a wholly owned subsidiary of Enstar while continuing to operate largely independently from its Lansing headquarters.

A Strategic Exit After Three Decades of Growth

Blue Cross Blue Shield of Michigan acquired AF Group in 1994. At that time, the organization operated as a state-owned entity with limited reach. Under Blue Cross ownership, AF Group expanded far beyond its original mandate and evolved into a national provider of property and casualty insurance, including workers’ compensation coverage for businesses across the country.

Tricia Keith, president and CEO of Blue Cross Blue Shield of Michigan, indicated that the subsidiary had reached a size and maturity that required alignment with a parent focused on property and casualty insurance rather than health care. Blue Cross remains primarily a health insurer, and rising medical costs continue to place pressure on affordability for members and employer groups.

The sale strengthens Blue Cross’s balance sheet and increases capital flexibility. In plain terms, it frees resources so the organization can concentrate on health insurance products and medical services rather than commercial insurance operations.

Why Enstar Wants AF Group

Enstar Group is a global insurance and reinsurance company with more than $22 billion in assets and over three decades of industry experience. The firm has built a reputation for acquiring and managing insurance businesses, particularly those with strong underwriting operations and specialized expertise.

AF Group fits that profile. The company has established itself as a significant player in workers’ compensation insurance, a niche that requires disciplined pricing, claims management, and long-term risk assessment. Workers’ compensation policies often remain active for years, and claims can develop slowly. That makes experience and financial strength especially valuable.

Sixth Street, the investment firm supporting the transaction, manages more than $125 billion in assets. Its involvement signals confidence in AF Group’s long-term profitability and growth prospects.

Continuity for Customers and Partners

Despite the change in ownership, AF Group is expected to continue operating largely as it does today. The company will keep its Lansing headquarters and maintain nationwide service to policyholders, brokers, and business clients.

Lisa Corless, president and CEO of AF Group, emphasized continuity. She noted the organization’s “people-first” culture and underwriting discipline as core strengths that will carry forward under Enstar’s ownership. In practical terms, customers should see little disruption in day-to-day operations.

For businesses that rely on workers’ compensation coverage, stability matters. Employers need insurers that will remain solvent and responsive for decades, not just a few policy cycles.

What the Deal Says About the Insurance Industry

This transaction reflects a broader trend: specialization. Large health insurers increasingly focus on medical coverage, care delivery, and cost management. Property and casualty insurers concentrate on commercial risks such as workplace injuries, liability, and property damage.

Combining both under one corporate roof can work, but it can also dilute focus. Selling AF Group allows Blue Cross to sharpen its mission. Acquiring AF Group allows Enstar to expand deeper into commercial insurance lines where it already has expertise.

Think of it as a corporate version of “stay in your lane.” Each organization moves closer to its core business, which often leads to clearer strategy and stronger performance.

Advisers Behind the Transaction

Several major firms supported the deal. J.P. Morgan Securities LLC served as exclusive financial adviser to Blue Cross Blue Shield of Michigan. Debevoise & Plimpton LLP provided legal counsel, and Milliman acted as actuarial adviser. These roles are typical in large insurance transactions, where financial modeling, regulatory compliance, and risk analysis are critical.

The financial terms were not disclosed, which is common when private companies are involved.

The sale of AF Group marks the end of a 32-year partnership between the insurer and Blue Cross Blue Shield of Michigan. It also positions both organizations to pursue clearer strategic paths. Blue Cross can concentrate on health care affordability and member services. Enstar gains a well-established national insurer with strong underwriting capabilities. If regulatory approvals proceed as expected, the transaction will stand as one of the more significant insurance deals of 2026.

The post Blue Cross Sells AF Group to Global Insurer in Strategic Shake-Up appeared first on Health Plan News.

China is aging at a pace that transforms how society works, spends, and plans. A report from WallstreetCN highlights a difficult truth: retirement and long life are becoming the rule, not the exception. At the same time, the number of seniors in China continues rising. By the end of 2024, individuals aged 60 and above reached 310 million, which is 22% of the population. Projections place this group at roughly 30% by 2035. These figures are not just statistics. They are a preview of a new social structure.

Taikang Insurance Group, one of China’s largest financial institutions, believes the solution is more than paperwork and policies. The company refers to its model as “New Life Insurance,” a system that links payments, services, and investments into one connected framework. That structure attempts to offer practical help instead of a simple transaction. Founder Chen Dongsheng calls this a “three-pronged synergy” that expands beyond traditional insurance and supports people as they age.

How the Problem Took Shape

The United Nations’ World Population Prospects report states that life expectancy exceeds 75 years in half of all countries. Longer life means more income is needed after retirement, more healthcare costs, and more long-term planning. It is easy for a young person to picture the next five years but almost impossible to picture the last twenty. At the same time, China’s pension reserves continue to face strain from increased payouts.

To address this, China has developed a personal pension system and tested commercial pension products. The government is building a foundation that encourages insurance companies, real estate developers, healthcare providers, and financial institutions to take part. In that environment, Taikang chose a direct strategy: enter the senior care business itself instead of outsourcing it.

The Shift in the Senior Population

A new perspective on aging is spreading. Japanese media showed individuals aging alone ten years ago. Now, entertainment and research suggest a calmer outlook, where later years can include fitness, leisure, and social strength. Data shows older adults want more than basic needs. A survey by Taikang and AgeClub, which reviewed the habits of 1,500 seniors, found a 17% year-over-year increase in visits to retirement communities in 2022. People want excitement, dignity, and a sense of place.

Senior care communities have different formats. In the United States, the industry includes Active Adult Communities that resemble vacation towns, Nursing Communities for more fragile individuals, and Continuing Care Retirement Communities that extend support as health changes. Japan uses retail-based community hubs where convenience stores help manage daily needs. China’s standout trait is that insurance companies — not only property developers — often lead the development of senior living campuses.

Why Insurance Groups Are Entering Real Estate and Healthcare

Insurance companies control large pools of capital. A retirement community, once operating successfully, can produce steady income and rise in property value. U.S. data from CBRE showed that senior housing delivered an annualized return of 14.6% from 2004 to 2018. Those numbers outperform many types of commercial real estate. Taikang appears to have used this logic early.

Since 2007, Taikang has funded hospitals, retirement projects, and wellness campuses. Its first large senior community pilot gained regulatory approval in 2009. In 2012, the “Happiness Plan,” a long-term annuity linked to physical community access, launched and marked a turning point — insurance payments began to connect to a physical place and a real lifestyle.

The New Life Insurance Model Explained

The “New Life Insurance” model adds a service end to the traditional pairing of liabilities and investments. Liabilities refer to long-term policy obligations. Investments refer to the capital managed by the insurance company. The new third component — services — refers to real hospitals, senior homes, end-of-life care, and wellness programs that clients can use.

Taikang argues this model cures several issues. A low interest-rate economy makes investment returns unpredictable. Building high-return assets such as retirement campuses supports insurance products. Insurance products provide long-term client funding. Healthcare and wellness services increase customer stickiness and sales. Each part fuels the other.

Many major Chinese competitors have waited on the sidelines. Taikang took a harder road by building communities itself, which requires capital and patience. It now operates 47 projects across 37 cities and houses more than 20,000 residents. Its products now include the Longevity Plan, Health Plan, Wealth Plan, and Graceful Aging Plan. More than 300,000 clients participate. Over 20,000 licensed planners sell and manage these offerings.

Lessons From Abroad

History shows that missing timing can destroy dominance. In the United States, life insurers once controlled retirement planning. As investment funds and asset managers expanded, traditional life insurance lost relevance. Premium contributions fell from almost 80% of pension assets in 1950 to under 30% today. Real estate developers and REITs now shape U.S. senior communities instead of insurance companies.

Chen Dongsheng appears determined to avoid that outcome. His book Strategy Determines Everything explains that the window is small. Delay could leave the industry irrelevant or worse — bankrupt. His message is blunt: industries fall when they wait too long.

Why This Matters Beyond Finance

Aging is personal. It is also social. Individuals worry about loneliness, care quality, cost, and dignity. Families worry about distance, responsibility, and emotional weight. A system that combines housing, medical care, and long-term finance is more than a business model. It sets a social tone: aging is not a sentence; it is a stage.

In 2025, Taikang continued to post revenue growth, new business growth, and net profit growth. Its solvency remains strong. The numbers show that the company’s strategy is working — at least for now.

Taikang is telling a Chinese story that can be heard internationally. Time will show whether this formula becomes a blueprint for others. For a country facing a gray future, it may become one of the most defining experiments of this era.

The conversation is not over. But Taikang has planted a flag, and anyone in the insurance industry would be wise to watch where this model goes.

The post From Insurance to Senior Living Cities: Taikang’s Massive Bet No One Saw Coming appeared first on Health Plan News.

New analysis from KFF shows average ACA marketplace premiums rising by 26%. That increase lands before factoring in enhanced tax credits set to expire at the end of the year. Without those credits, some plans could see costs soar far beyond what households paid just a year ago.

Premium Increases Vary, Pain Does Not

The increases differ by state, income, age, and family size. The result still lands the same. Higher monthly bills.

North Carolina residents face increases ranging from 16% to 34%. Ohio follows with hikes between 13% and 17%. Texas and Florida sit near the top at roughly 35% and 34%. Pennsylvania lands closer to 21%.

Many families attempt to soften the blow by selecting lower-tier plans. That strategy often backfires. Deductibles above $7,000 are becoming common. Paying thousands before coverage starts leaves many feeling uninsured in practice, even with a plan in hand.

Searching for Relief Outside Traditional Insurance

As premiums climb, alternatives draw renewed attention. Healthcare sharing ministries are seeing sharp interest, led by organizations like :contentReference[oaicite:0]{index=0}.

Liberty HealthShare reports inquiry levels unseen since the end of the ACA tax penalty. November 2025 inquiries jumped more than 300% compared to the same month a year earlier. Enrollment growth has continued for 27 straight months. November marked the highest monthly enrollment in over three years. December trends point even higher.

Dorsey Morrow, chief executive officer of Liberty HealthShare, frames the shift plainly. Paying $12,000 before benefits kick in does not feel like coverage to many families. For them, the math no longer works.

How Healthsharing Works in Practice

Healthsharing is not insurance. That distinction matters. Members voluntarily share eligible medical expenses with one another rather than paying premiums to an insurer. There are no ACA mandates. There are clear sharing guidelines.

Liberty HealthShare encourages prospective members to review those guidelines carefully. Some expenses qualify. Others do not. The tradeoff comes down to cost structure, values, and personal risk tolerance.

Eligible medical expenses are typically shared within 30 to 45 days. For many members, that timeline offers predictability without traditional insurer friction.

Faith-Based Structure and Financial Impact

Liberty HealthShare operates as a nonprofit Christian ministry built on voluntary monthly contributions. Members help shoulder one another’s medical needs. The structure follows a stewardship model rather than a claims model.

In the past year, members shared more than $454 million in billed medical charges. Those charges were repriced to just over $154 million. The result delivered more than $300 million in savings. Since 2014, nearly $5 billion in eligible medical expenses have been shared.

Those figures explain why enrollment momentum continues even as healthcare costs rise across the country.

Programs, Pricing, and Flexibility

Liberty HealthShare offers six medical cost sharing programs. Individual monthly share amounts range from $87 to $362. A family of four can start near $319 per month. Most programs include urgent care access, mental wellness telehealth visits, and prescription discounts.

Liberty Dental allows members to visit any dentist with no network restrictions. Monthly share amounts begin around $35.

Liberty Vision covers eye exams, glasses, contact lenses, and LASIK procedures. Monthly share amounts start at $7 for individuals.

Transparency and Oversight

Liberty HealthShare holds Candid’s 2025 GuideStar Gold Seal and a Charity Navigator four-star rating. It also maintains Better Business Bureau accreditation with an A+ rating. These distinctions place it in a small group of nonprofit organizations meeting high accountability standards.

Enrollment remains open year-round. No qualifying life events are required. That flexibility contrasts sharply with traditional ACA enrollment windows.

Earlier this year, Liberty HealthShare launched the Sharing Hearts Fund for Pediatric Wellness. The fund supports families in Stark County, Ohio with pediatric medical needs, extending the ministry’s community reach.

Healthcare costs continue to rise. Families continue to look for workable options. For some, healthsharing offers relief that standard plans no longer provide. For others, it sparks a necessary conversation about how healthcare should function when affordability slips out of reach.

The post Americans Brace for 2026 Health Insurance Sticker Shock appeared first on Health Plan News.

The money will cover students entering the 2026 cohorts. Training kicks off in January 2026. Students can choose full-time or part-time tracks. Both options require 710 hours of instruction. Graduates walk away ready to work as medical assistants in San Diego’s healthcare facilities.

Building Tomorrow’s Healthcare Workers Today

Jennifer Schirmer serves as vice president of Medi-Cal growth and community engagement for Blue Shield Promise. She framed the scholarship program as an opportunity builder. “This initiative is about more than funding — it’s about creating opportunity,” Schirmer said. “By investing in local talent and expanding educational opportunities, we’re helping to grow the next generation of healthcare professionals who will strengthen San Diego’s healthcare system by increasing the number of trained health professionals in the region.”

The funding approach here differs from typical scholarship models. Most LRMAI scholarships come with strings attached—employment requirements, repayment clauses, that sort of thing. Blue Shield Promise’s $80,000? No strings. Recipients can pursue jobs anywhere across San Diego’s healthcare workforce. That’s rare flexibility in medical training programs, where students often commit to specific employers or face financial penalties.

Addressing Real Gaps in Healthcare Access

San Diego County faces a persistent healthcare worker shortage. Low-income and medically underserved communities feel this shortage most acutely. Medical assistants serve as critical links between patients and providers. They take vital signs, update medical histories, prepare exam rooms, and handle administrative tasks that keep clinics running.

Fran Butler-Cohen, CEO of Family Health Centers of San Diego, connected the scholarship program to broader community health needs. “Blue Shield Promise’s scholarship sponsorship directly invests in the people who will shape the future of community health care across our region,” Butler-Cohen said. “By expanding access to medical assistant training, we’re creating career pathways that address workforce shortages and improve access to care for all San Diegans.”

The 710-hour program covers clinical procedures, administrative operations, patient communication, and electronic health records (EHR) management. Students learn phlebotomy, medication administration, medical terminology, and HIPAA (Health Insurance Portability and Accountability) compliance. The curriculum aligns with California’s certification requirements for medical assistants.

A Partnership with History

This scholarship commitment extends an existing relationship between Blue Shield Promise and Family Health Centers of San Diego. The partnership launched in 2022 with a $1 million grant. That initial investment expanded cardiac care services in eastern San Diego County. It also funded the El Cajon Urgent and Cardiac Care Center, which opened its doors to address cardiovascular health needs in a traditionally underserved area.

Blue Shield of California Promise Health Plan operates as a managed care organization offering Medi-Cal coverage. The organization serves approximately 580,000 members across Los Angeles and San Diego counties. NCQA (National Committee for Quality Assurance) rated the health plan 4 out of 5 in its Medicaid Health Plan Ratings 2024.

Healthcare professionals lead the organization with what they call a “members-first” philosophy. The approach prioritizes building provider networks and partnering with community organizations that serve uninsured, low-income, and medically underserved populations.

What Comes Next

Family Health Centers of San Diego will host an open house for prospective students on Tuesday, December 16. The event runs from 4 p.m. to 6:30 p.m. at the Oak Park Family Health Center, located at 5160 Federal Blvd. #150, San Diego, CA 92105.

Interested candidates can learn about program requirements, application processes, and scholarship availability. Staff will be on hand to answer questions about curriculum structure, clinical training sites, and job placement support.

The timing of this scholarship announcement matters. Healthcare staffing shortages continue to strain medical facilities nationwide. Medical assistants represent one of the fastest-growing occupations in healthcare, according to U.S. Bureau of Labor Statistics projections. The profession requires less training time than nursing or physician assistant programs, making it an accessible entry point for people seeking stable healthcare careers.

San Diego’s healthcare landscape includes major hospital systems, community health centers, specialty clinics, and urgent care facilities. All need qualified medical assistants. This scholarship program removes a significant financial barrier for people who want to enter the field but lack resources for tuition and training materials.

The $80,000 investment will fund multiple students through comprehensive training. Each scholarship covers program costs, study materials, and exam fees for certification. Blue Shield Promise’s decision to waive employment and repayment requirements gives graduates genuine career mobility. They can choose employers based on fit, location, and professional goals rather than contractual obligations.

This kind of workforce development investment benefits everyone in the healthcare ecosystem. Patients get more access to care. Healthcare facilities can fill critical staffing gaps. Students gain marketable skills and stable employment opportunities. Communities see improved health outcomes when medical services become more available and accessible.

The post Blue Shield Promise Puts $80K Behind San Diego’s Future Medical Assistants appeared first on Health Plan News.

If you buy health coverage through the Affordable Care Act (ACA) marketplaces, you might want to sit down. A new report from ValuePenguin by LendingTree is sounding the alarm. It’s loud. The average cost for the most popular plans will jump by a whopping 21% across the country in 2026. That’s not a typo. That’s a serious hit to your bank account.

This isn’t just a small price increase. This is a huge change. Talon Abernathy, a health insurance expert at ValuePenguin, said it clearly: these big increases will take a much bigger chunk out of family budgets next year. It’s a bitter pill to swallow. It makes it hard to make ends meet.

The Silver Plan Shockwave

The Silver-tier plan is the top choice on the marketplace. It’s the one most people pick. Well, listen up: the average price for a Silver plan is now hitting a record $752 every month. This is before any help from the government. Think about that number. It’s a huge amount of money.

For some perspective, these plans are now 77% more expensive than they were just five years ago. That’s a shocking jump. It shows how fast the cost of staying healthy is going up. It’s enough to make anyone feel a little queasy.

Where the Pain is Worst

Almost every state is feeling the heat. Prices are going up in all 50 states. Forty-five of those states are seeing increases of more than 10%. That’s nearly the whole map turning red.

Some places are getting absolutely crushed. Arkansas, for example, is looking at the biggest climb. Rates are going up by 67%. Ouch! Mississippi and Washington also face huge hikes of 40% or more. It’s a real mess. Only Alaska gets a break. They will see a small 5% drop. Good for them!

The Subsidy Safety Net is Fraying

The extra help that people got in 2025 is going away. This is where things get truly bad for some folks. Without that support, the average cost for a subsidized plan could shoot up. It goes from $84 a month to $175 a month. That’s more than double the price.

People earning around $30,000 a year face the roughest time. Their premiums could spike by a massive 216%. Picture getting a bill that’s three times bigger than last year’s. It’s a financial punch to the gut.

Big Insurers Are Raising the Stakes

The four biggest health insurance companies are all raising prices. Ambetter is leading the way with a 38% increase. UnitedHealthcare is close behind at 30%. Blue Cross Blue Shield is raising rates by 28%. Even Kaiser Permanente is adding 17% to the bill. Everyone is feeling the squeeze.

What You Can Do Right Now

Mr. Abernathy has some solid advice. He knows health insurance isn’t the first thing on your mind during the holidays. But he says spending a little time now could save you a lot of money later. It’s a classic case of a stitch in time saving nine.

You need to compare plans. You need to check for any help or discounts you might still get. Look at the different metal tiers and plan types. Don’t just let your plan renew itself. Doing your homework could mean the difference between a manageable bill and a budget disaster. Don’t let this huge cost increase catch you off guard. Get smart, get shopping, and protect your pocketbook. This is one battle you can actually win if you act fast.

The post The Great Health Insurance Heist: 45 States Hit with Double-Digit Rate Hikes! appeared first on Health Plan News.

And yes—there is one firm that separates itself from the rest.

1. Van Wey & Metzler – Dallas, Texas

Van Wey & Metzler holds the top spot on this year’s list for good reason. The team has built a national reputation by taking on high-impact medical injury cases, including the notoriously shocking Dr. Death case. Their work on that case made waves because it exposed how multiple systems failed to protect patients—a topic that still resonates nationwide.

The firm continues to push for medical accountability and better patient protections, not just in the courtroom but also through public education. Their new health-focused podcast, AdvoKAYte, brings clear, candid conversations about patient safety, lawsuits, medical errors, and real cases that changed lives. Van Wey & Metzler combines courtroom results with patient advocacy in a way that few firms attempt—and even fewer execute well.

2. Levin & Perconti – Chicago, Illinois

Known for substantial verdicts and a long track record of high-value medical injury cases, Levin & Perconti remains one of the most recognized names in the country. They frequently handle severe birth injury, surgical error, and nursing home negligence cases.

3. The Cochran Firm – Nationwide

With offices across major U.S. cities, The Cochran Firm tackles a large volume of complex malpractice cases. Their team handles misdiagnosis, anesthesia errors, and profound surgical mistakes, often resulting in significant settlements.

4. Morgan & Morgan – Nationwide

Morgan & Morgan is widely known for personal injury work, but their medical malpractice division consistently secures strong results. Their national footprint gives them access to extensive resources for litigation, research, and expert testimony.

5. Janet, Janet & Suggs – Baltimore, Maryland (National Practice)

This firm is known for some of the largest birth injury and brain injury verdicts in U.S. history. Their medical-legal team includes former healthcare professionals, which sets them apart in case investigation and strategy.

6. Paulson & Nace – Washington, D.C.

A family-run firm with multiple landmark verdicts, Paulson & Nace focuses heavily on cancer misdiagnosis, obstetrical negligence, and catastrophic medical injuries. Their reputation stems from high courtroom success rates and aggressive trial preparation.

7. Salvi, Schostok & Pritchard – Chicago, Illinois

This Illinois-based firm handles high-stakes malpractice lawsuits and consistently ranks among the top firms for large surgical error and delayed treatment verdicts.

8. Freese & Goss – Dallas, Texas

Freese & Goss has a long history of handling medical device litigation and hospital negligence cases. They’re known for taking on large, systemic failures involving corporate healthcare defendants.

9. Kline & Specter – Philadelphia, Pennsylvania

With multiple attorneys also holding medical degrees, Kline & Specter stands out for its ability to take complicated medical arguments to trial. Their reputation in obstetric and surgical malpractice cases is strong nationwide.

10. Lubin & Meyer – Boston, Massachusetts

A powerhouse in New England, Lubin & Meyer leads the region in medical malpractice verdicts. They frequently secure significant settlements for birth injuries, delayed diagnosis, and emergency room negligence.

The post 10 Medical Malpractice Law Firms Reshaping Patient Justice in 2025 appeared first on Health Plan News.

For a market where people compare weekly injections the way others compare phone upgrades, this is a big reset. It is about cost, yes. It is also about who gets access to authentic, FDA-approved semaglutide instead of mystery vials from a pop-up website.

How the $199 Intro Offer Actually Works

The offer applies to new self-pay patients in the United States starting November 17, 2025. It runs through March 31, 2026, and covers the two lowest doses of Wegovy or Ozempic: 0.25 mg and 0.5 mg. These are the early titration doses that most people use during the first two months as they adjust to treatment.

Those first two months come in at $199 per month for patients who are paying out of pocket. That is a clear price tag. No rebate spreadsheets. No loyalty points. Just a lower sticker price at the pharmacy counter for the starter phase.

What Happens After the First Two Months

After the introductory period, patients move to the new standard self-pay price of $349 per month for Wegovy and most Ozempic strengths. That figure reflects a drop from the prior self-pay price of $499 per month. The higher 2 mg strength of Ozempic remains at $499 per month under this structure.

From a consumer standpoint, the typical pattern looks like this: two months at $199 a month for the starter doses, then $349 per month for ongoing treatment, unless the prescription is for Ozempic 2 mg, which stays at $499. For people who have been staring at cash prices near or above $500, a cut of $150 per month is easy to understand.

Why Novo Nordisk Moved Early on Self-Pay Pricing

This change did not appear out of thin air. Novo Nordisk already agreed with the US Administration to lower prices in the direct-to-patient self-pay channel in 2026 as part of a broader push on access and affordability. Instead of waiting for the calendar to roll over, the company is dragging those prices forward into late 2025.

In simple terms, they are pulling the future discount into the present. That lets the company say two things at once: they heard criticism about affordability, and they want more people using FDA-approved semaglutide instead of chasing bargain injections from unknown sources.

As Dave Moore, Executive Vice President for US Operations at Novo Nordisk, points out, the US health system has layers: different insurance models, coupon programs, telehealth, big-box pharmacies, and employer benefits that rarely look alike. A direct self-pay price cut gives patients one clear number they can plan around, even if their insurance coverage is patchy or nonexistent.

Where Patients Can Use the New Self-Pay Offers

Novo Nordisk is not limiting these prices to a narrow channel. The offers flow through multiple access points:

• Wegovy.com and Ozempic.com, where patients can register and then use savings with a prescription at more than 70,000 pharmacies across the United States.
• NovoCare Pharmacy, which allows prescribers to send scripts directly and gives patients the choice of home delivery or pickup at more than 9,000 CVS retail locations.
• Partner organizations and select telehealth providers, including Costco, GoodRx, WeightWatchers, Ro, LifeMD, and eMed.

“I spend more time talking about semaglutide than blood pressure medicine now,” one primary care doctor joked to me recently. This offer lines up with that reality. Patients want predictable pricing where they already shop, whether that is a neighborhood pharmacy or a wholesale club.

What “Self-Pay” Means in Plain Language

In this context, self-pay refers to patients who pay cash for their prescription instead of using pharmacy benefits through an insurance plan. Some people fall into that bucket because their plan excludes weight-loss medication. Others choose to pay cash because they want to avoid prior authorization battles or restrictive coverage rules.

For those patients, self-pay pricing functions like a sticker price in retail. The $199 introductory offer and $349 ongoing price sit beside whatever their local pharmacy charges for visit fees, counseling, or delivery. There is no guarantee that the total cost of care stops at the drug label, but the medication line item gets far more predictable.

Where Insurance Still Fits In

These offers sit alongside, not in place of, savings programs for patients who have commercial insurance coverage. For eligible patients with coverage, Novo Nordisk continues to promote co-pay programs that can bring Wegovy down to as little as $0 per month and Ozempic down to $25 per month.

That split matters. If a patient has strong coverage and qualifies for a co-pay card, those programs can beat the self-pay rate. If coverage is missing or limited, the new $199 starter price and $349 ongoing option set a clear ceiling on out-of-pocket drug cost, at least for the covered doses.

GLP-1, Semaglutide, and Why These Drugs Matter

Both Wegovy and Ozempic are part of the GLP-1 class. GLP-1 stands for “glucagon-like peptide-1,” a hormone that helps regulate appetite and blood sugar. Semaglutide, the active ingredient in both products, mimics that hormone and acts on receptors in the body that influence hunger signals, glucose levels, and long-term metabolic patterns.

Wegovy is approved for adults and some adolescents with obesity, as well as adults with overweight plus certain weight-related conditions. It also carries an indication to reduce the risk of major cardiovascular events in adults with heart disease who live with obesity or overweight. Ozempic is approved for adults with type 2 diabetes to improve blood sugar and to lower the risk of serious cardiovascular events, and it has an indication related to chronic kidney disease in that same group.

Millions of patients in the United States already use semaglutide under one of these brand names. For them, this is not a vanity play. It is long-term disease management that touches weight, blood sugar, heart risk, kidney health, and quality of life in one package.

Safety: The Warnings Patients Cannot Ignore

These are serious prescription drugs, not casual wellness shots from a strip mall. Both labels carry warnings about a possible risk of thyroid tumors, including a rare type called medullary thyroid carcinoma. People with a personal or family history of that cancer, or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), are told not to use these medicines.

The safety sections also flag pancreatitis, gallbladder issues, low blood sugar (especially in combination with insulin or sulfonylureas), kidney problems tied to dehydration, severe stomach issues, changes in vision for people with diabetes, increases in heart rate, and mental health changes such as depression or suicidal thoughts. That list is long on purpose. GLP-1 therapy changes how the gut and brain handle food and appetite, and that can ripple through other organs.

The practical takeaway is simple. Patients need a real conversation with a clinician who understands their history. They should mention prior pancreatitis, kidney disease, eye complications from diabetes, severe stomach slowing, and any mental health history before the first injection. They also need to tell surgeons and anesthesiologists that they use semaglutide before procedures that require deep sedation.

Obesity and Type 2 Diabetes: The Bigger Picture

Obesity is a chronic disease, not a character flaw. Biology, genetics, environment, and social factors all shape weight. A stubborn narrative still claims that people could solve everything with willpower and fewer snacks. That narrative does not match the data.

Roughly 40 percent of adults in the United States live with obesity. More than 28 million people have type 2 diabetes. That is about 9.4 percent of the population. Those numbers are not small pockets of people; they are neighbors, relatives, and co-workers.

People with type 2 diabetes face two to four times the risk of cardiovascular disease compared with those who do not have diabetes. For them, glucose control is only one part of the story. Reducing heart attack and stroke risk is just as important. That is where GLP-1 drugs with cardiovascular indications step into the picture.

Lifestyle changes still matter a lot. Healthy eating, physical activity, and regular monitoring remain the backbone of treatment. Medications like Wegovy and Ozempic do not replace that work. They give biology some backup, especially for people who hit a wall with lifestyle changes alone.

Authentic vs. Compounded “Semaglutide”

Novo Nordisk is also sending a message to the gray market. Compounded “semaglutide” products have flooded social media feeds and discount sites. Some may use salt forms or ingredients that have not gone through the same FDA approval process as Wegovy and Ozempic. Others might not contain semaglutide at all.

Lower, clearer pricing on the original products trims one of the main excuses for chasing unverified sources. Patients can still fall for knockoffs, but the price gap narrows. That makes pharmacists, prescribers, and patients more likely to stay inside the regulated channel, which is exactly where a drug with serious risks belongs.

From a brand perspective, this is a defensive move as well as an access move. You do not want fake versions of your marquee products defining consumer expectations. You want people talking about real outcomes from verified pens, not mystery vials shipped in a padded envelope with no lot tracking.

What Patients and Care Teams Should Do Next

Patients who already use Wegovy or Ozempic on a self-pay basis should talk with their prescribing clinician or pharmacist about the new structure. They need to confirm which price applies to their dose, and whether they qualify for the introductory offer or the ongoing $349 rate.

Patients with commercial insurance should also revisit coverage checks. A strong benefit plus a co-pay savings card can still beat the self-pay rate. On the other hand, if coverage has been denied or capped, the new pricing may finally bring a GLP-1 option into reach for the household budget.

Prescribers and care teams should update their talking points. That means explaining the difference between starter doses and maintenance doses, spelling out self-pay versus insurance pricing, and reminding patients to only use FDA-approved sources. A short script here can prevent a lot of confusion at the pharmacy counter.

From where I sit, wearing both a data hat and a consumer hat, the signal is clear. Novo Nordisk wants more patients on branded semaglutide at prices that feel less like a luxury purchase and more like a sustained medical expense that a family can plan around.

As always, none of this replaces medical advice from a clinician who knows the patient’s full history. But if you have been staring at GLP-1 headlines from the sidelines because the cash price looked out of reach, the numbers just moved. You now have an introductory window at $199 per month and a lower long-term self-pay price on the table. The next step is a clear conversation with your healthcare professional about whether Wegovy or Ozempic fits your health goals, your risks, and your budget.

The post Wegovy and Ozempic for $199 a Month? Novo Nordisk Just Rewrote the Self-Pay Rulebook appeared first on Health Plan News.

Kay Van Wey Launches AdvoKAYte Podcast to Expose Failures in American Healthcare

The American healthcare system has met one of its sharpest critics once again, and she now has a microphone. Attorney Kay Van Wey, known nationwide for her long track record of fighting medical negligence, has launched a new podcast called AdvoKAYte: Holding Healthcare Accountable. The show brings her forty years of experience straight to patients, families and caregivers, many of whom feel overwhelmed, ignored or dismissed by a system that too often puts profits ahead of safety.

In court, Van Wey has handled medical malpractice cases for decades. She has seen how hospitals and corporate health systems can hide behind layers of procedure as patients suffer the consequences. Her career includes hundreds of trials involving negligence and preventable harm. The podcast gives her a new way to lift those stories and highlight what goes wrong behind the scenes. She calls it a small contribution, but anyone familiar with her work knows her version of “small” carries weight.

The Story Behind the First Episode

The opening episode, titled “Exposing Medical Negligence,” sets the tone. Van Wey explains her path, from her rural upbringing to becoming one of the most recognized patient-safety advocates in the country. Many know her for her role in exposing the failures that allowed Texas neurosurgeon Christopher Duntsch — later known as “Dr. Death” — to keep practicing even as patients were left paralyzed or worse. Duntsch harmed 31 people and killed two others before he was stopped. Van Wey represented several of those families. Her work helped reveal how weak the oversight systems were, including state boards and hospital committees meant to protect the public.

Duntsch is now serving what amounts to a life sentence, with parole eligibility decades away. His victims will live with life-altering injuries forever. Van Wey reminds listeners that Duntsch wasn’t an isolated event. He was a symptom of structural problems that still exist. The regulatory mechanisms that allowed him to slip through remain largely untouched. The public rarely hears the full story about how these failures happen. That gap is exactly why she created the podcast.

Why Van Wey Believes This Work Still Matters

Throughout the episode, Van Wey shares hard-earned insight from her career. She speaks openly about situations she has witnessed — situations most patients never hear about until it’s too late. She describes unsafe care, administrative cover-ups and the quiet machine that protects bad actors once complaints begin to surface. These patterns repeat across the country. She knows because she has seen them case after case.

Her goal is to give patients a fair shot at protecting themselves. It’s also to warn families before they trust the wrong person with their care. Her words come with a steady message: every patient matters and every story carries value. When stories go unheard, the cycle continues.

Teaching, Speaking and Shaping the Conversation

Outside the courtroom, Van Wey teaches medical malpractice courses at law schools. She and her colleague Luke Metzler speak at legal conferences across the country. These talks give lawyers a clearer view of how negligence cases unfold and what signs often go unnoticed in hospitals. She’s spent her entire career raising awareness of how oversight has weakened and how easily mistakes turn into tragedies when institutions choose silence over transparency.

She says her work isn’t a calling — her phrasing is more subtle — but she acknowledges it’s her purpose. She believes her role is to help push the system to a point where reform becomes unavoidable. The podcast expands that mission by placing information directly into the hands of the people who need it most.

What the Podcast Aims to Cover

Listeners can expect deep looks at how healthcare corporations operate, how internal cover-ups form and why patients rarely learn the full truth after an adverse event. Co-host Kalee Dionne Pair joins her each week to break down stories that rarely surface in mainstream coverage. Their conversations highlight the mechanics behind medical negligence cases, legislative gaps and the common tactics used to shield repeat offenders.

A small sign taped to Van Wey’s computer reads, “Don’t look at your feet, just dance.” It says a lot about the energy behind her new series. She knows the system can feel overwhelming for the average person. She also knows someone has to speak plainly about what’s really happening, without legal jargon or corporate gloss.

The message to listeners is straightforward: bad medical outcomes aren’t always unavoidable. Many injuries can be prevented. Many deaths should never have happened. By exposing patterns of misconduct, Van Wey hopes to give families the information they should have received long before entering a hospital room.

Each weekly episode brings her closer to that goal. It gives her a direct line to the people who often feel powerless in healthcare settings. With AdvoKAYte, Van Wey is taking decades of courtroom experience and shifting it onto a platform where more people can learn how the system actually works — and how it should work instead.

This new project offers something many Americans have been seeking: a source that will call out preventable harm, question corporate behavior and remind listeners that patient safety should never depend on how a hospital’s balance sheet looks. The show is a firm push for accountability, delivered through the voice of someone who has been fighting these issues far longer than most. It’s an invitation for patients to pay attention, ask harder questions and demand safer care for themselves and their families.

The post New Podcast Takes Aim at the Dark Corners of Healthcare — Kay Van Wey Isn’t Holding Back appeared first on Health Plan News.